2034 年前長壽與健康老化技術市場預測：按技術類型分類的全球分析

根據 Stratistics MRC 的數據，預計到 2026 年，全球長壽和健康老化技術市場規模將達到 43 億美元，到 2034 年將達到 276 億美元，預測期內複合年成長率為 26.1%。

長壽和健康老化技術是治療方法、診斷、數位健康平台和輔助設備，旨在透過老齡化的生物機制來延長健康壽命並延緩與老齡化相關的疾病的發生。該市場包括老化細胞清除療法和基因療法、表觀遺傳重編程技術、幹細胞療法、NAD+代謝調節劑、利用多組體學分析的生物衰老平台、穿戴式健康監測設備、人工智慧驅動的預測分析以及居家養老支持系統。

對長壽科學的投資呈指數級成長，並檢驗了突破性治療方法。

前所未有的創業投資和企業對長壽科學的投資正在加速實驗室發現向臨床候選藥物和市售健康最佳化產品的轉換。突破性研究在動物模型中證實了表觀遺傳再程式化、衰老細胞清除和部分細胞再生等技術，​​極大地激發了投資者的興趣，並為開發針對衰老潛在生物學機制的干預措施奠定了科學基礎。富裕人士和主權財富基金正在投資專注於長壽的生物技術公司、長壽診所和精準診斷平台，從而形成投資、創新和市場擴張的良性循環，從根本上改變我們對待老年人醫療保健的方式。

缺乏針對老化作為治療標靶的檢驗的臨床終點和監管途徑。

長壽療法面臨的一項核心科學和監管挑戰是缺乏普遍認可的衰老生物標記作為臨床終點，這使得關鍵臨床試驗的設計和監管申報變得複雜。目前，美國食品藥物管理局（FDA）尚未將老化本身認定為一種疾病，這限制了針對生物老化機制的干預措施的直接監管途徑。開發經驗證的「老化時鐘」或衰退生物標記，並使其被監管機構接受作為長壽療法的替代終點，是該治療領域商業化的根本前提。臨床試驗週期的延長以及檢驗要求的增加，檢驗了資金消耗週期，為早期長壽相關企業的財務模式帶來了挑戰。

針對一般消費者的生物年齡測試和個人化長壽最佳化服務

透過表觀遺傳時鐘檢測、蛋白質體學分析和多體學平台，便利的生物年齡檢測技術的商業化正在催生一個面向消費者的個人化長壽評估和最佳化項目市場。提供全面診斷檢測，並結合個人化營養補充、生活方式指導和治療性介入方案的長壽診所，正吸引全球富裕的早期使用者。隨著定序技術的普及和檢測成本的降低，生物年齡的測量正從學術研究領域走向消費者醫療保健服務。那些建構人工智慧驅動的個人化長壽指導平台，並整合穿戴式生物辨識設備的科技公司，有望佔據大規模的消費者市場佔有率。

檢驗的延年益壽補品氾濫，以及圍繞抗衰老功效的倫理問題。

長壽技術的快速商業化導致大量營養補充劑和保健品湧現，這些產品聲稱具有未經證實的抗衰老功效，削弱了消費者對整個長壽市場的信心，並引發了監管機構日益嚴格的審查。實證長壽介入措施與健康行銷之間的界線日益模糊，為那些秉持嚴格科學標準的信譽良好的臨床階段公司和長壽診所帶來了聲譽風險。圍繞著長壽技術公平獲取、基於壽命的潛在社會分層以及健康壽命大幅延長帶來的社會影響等倫理爭議，進一步加劇了法規環境性，並影響了公眾對這一新興市場的看法。

新型冠狀病毒（COVID-19）的影響：

新冠疫情提高了大眾對老齡化相關免疫系統脆弱性的認知，並加速了消費者對積極健康最佳化和以延年益壽為重點的預防策略的興趣。疫情期間，人們健康意識的提升促使數百萬人開始專注於生物年齡檢測、營養補充計畫以及與延長健康壽命相關的健康生活方式改變。在封鎖期間，人們有時間反思自身健康狀況並積極使用數位健康服務，這為長壽平台提供者帶來了益處。疫情後，人們對健康問題的關注度持續提升，包括免疫力、代謝健康和老化生物學等方面，從而為長壽和健康老化技術市場創造了持續的文化和商業性動力。

在預測期內，「延壽治療」細分市場預計將佔據最大佔有率。

在加速推進老化細胞清除劑、基因和細胞療法以及NAD+代謝調變器藥物臨床開發平臺的推動下，長壽療法領域佔據了長壽和健康老化技術市場的最大佔有率。專注於長壽領域的製藥公司和生技公司正投入大量資源，開發針對老化顯著特徵（例如細胞老化、粒線體功能障礙和表觀遺傳失調）的干預措施。

預計在預測期內，「診斷和生物標記技術」細分市場將實現最高的複合年成長率。

診斷和生物標記技術預計將在長壽市場中實現最高的複合年成長率，這反映出人們越來越需要客觀地測量治療和生活方式乾預前後生物老齡化的進程。表觀遺傳時鐘測試、基於蛋白質組學的生物年齡檢測以及人工智慧驅動的多組體學平台正從調查工具轉向商業診斷服務。隨著長壽療法臨床試驗的擴展，檢驗的生物標記技術將成為證明療效的關鍵基礎，有助於醫療機構和生物製藥公司採用這些技術，並透過長壽診所和數位健康平台直接向公眾推廣。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率。北美在全球長壽和健康老齡化技術市場中佔據主導地位，這反映了該地區集中了眾多專注於長壽的生物技術公司、世界一流的研究型大學以及強大的創業投資基礎，這些風險投資主要集中於資助該地區的老齡化生物學研究。美國擁有大多數處於臨床階段的長壽藥物研發公司、一個商業性長壽診所網路以及一個高度活躍且富裕的消費群體，他們願意投資高階健康最佳化服務。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率。受日本人口老化加劇、中國對生物技術和老化研究的策略性國家投資，以及韓國、新加坡和澳洲富裕消費者群體快速成長對高階長壽和健康服務的需求等因素的推動，亞太地區預計將在長壽和健康老齡化技術市場實現最高的複合年成長率。各地區政府正積極推動對老化研究聯盟的資助，並建立長壽療法監管沙盒。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

• 企業概況
  • 對其他市場參與者（最多 3 家公司）進行全面分析
  • 對主要公司進行SWOT分析（最多3家公司）
• 區域分類
  • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
• 競爭性標竿分析
  • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

• 市場概覽及主要亮點
• 促進因素、挑戰與機遇
• 競爭格局概述
• 戰略洞察與建議

第2章：研究框架

• 研究目標和範圍
• 相關人員分析
• 研究假設和限制
• 調查方法

第3章 市場動態與趨勢分析

• 市場定義與結構
• 主要市場促進因素
• 市場限制與挑戰
• 投資成長機會和重點領域
• 產業威脅與風險評估
• 技術與創新展望
• 新興市場/高成長市場
• 監管和政策環境
• 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

• 波特五力分析
  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭
• 主要公司市佔率分析
• 產品基準評效和效能比較

第5章：全球長壽與健康老化技術市場：依技術類型分類

• 延壽藥物
  • 種族學和種族治療學
  • 基因和細胞療法
  • 幹細胞療法
  • 表觀遺傳再程式化技術
  • NAD+和代謝療法
  • 再生醫學技術
• 診斷和生物標記技術
  • 生物年齡測試
  • 表觀遺傳時鐘
  • 多組體學平台
  • 人工智慧驅動的預測分析
  • 基因組學和蛋白​​質組學檢測
• 數位健康和​​監測技術
• 認知與心理健康技術
• 面向老年人的居家支援技術
• 健康與復健技術

第6章：全球長壽與健康老化技術市場：依產品類型分類

• 軟體平台
• 裝置和穿戴式裝置
• 診斷試劑盒和檢測服務
• 治療藥物和藥品
• 營養保健品和補充劑
• 智慧家庭和輔助設備
• 機器人和自動化系統

第7章 全球長壽與健康老化科技市場：依部署模式分類

• 基於雲端的解決方案
• 本地部署解決方案
• 混合解決方案

第8章：全球長壽與健康老化技術市場：依分銷管道分類

• 直銷
• 線上平台
• 專科診所
• 零售藥房
• 健康中心
• 電子商務平台

第9章：全球長壽與健康老化技術市場：依應用領域分類

• 延長健康壽命
• 預防性醫療保健
• 慢性病管理
• 神經退化性疾病的管理
• 代謝健康管理
• 行動輔助和康復
• 認知功能改善
• 遠距老年護理
• 個人化健康管理

第10章 全球長壽與健康老化科技市場：依最終用戶分類

• 醫院和診所
• 長壽診所
• 研究機構和學術機構
• 居家照護環境
• 高齡住家周邊設施
• 健康健身中心
• 一般消費者用戶
• 保險和醫療保健提供者

第11章 全球長壽與健康老化科技市場：按地區分類

• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 英國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 荷蘭
  • 比利時
  • 瑞典
  • 瑞士
  • 波蘭
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 韓國
  • 澳洲
  • 印尼
  • 泰國
  • 馬來西亞
  • 新加坡
  • 越南
  • 其他亞太國家
• 南美洲
  • 巴西
  • 阿根廷
  • 哥倫比亞
  • 智利
  • 秘魯
  • 其他南美國家
• 世界其他地區（RoW）
  • 中東
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 以色列
    • 其他中東國家
  • 非洲
    • 南非
    • 埃及
    • 摩洛哥
    • 其他非洲國家

第12章 策略市場資訊

• 工業價值網路和供應鏈評估
• 空白區域和機會地圖
• 產品演進與市場生命週期分析
• 通路、經銷商和打入市場策略的評估

第13章 產業趨勢與策略舉措

• 併購
• 夥伴關係、聯盟和合資企業
• 新產品發布和認證
• 擴大生產能力和投資
• 其他策略舉措

第14章：公司簡介

• Altos Labs
• Calico Life Sciences
• Unity Biotechnology
• Retro Biosciences
• Insilico Medicine
• Juvenescence
• BioAge Labs
• NewLimit
• Life Biosciences
• Rejuvenate Bio
• Gero
• Turn Biotechnologies
• AgeX Therapeutics
• Genflow Biosciences
• Oisin Biotechnologies

According to Stratistics MRC, the Global Longevity and Healthy Aging Technologies Market is accounted for $4.3 billion in 2026 and is expected to reach $27.6 billion by 2034, growing at a CAGR of 26.1% during the forecast period. Longevity and Healthy Aging Technologies represent a convergent field encompassing therapeutics, diagnostics, digital health platforms, and assistive devices targeting the biological mechanisms of aging to extend healthspan and delay the onset of age-related disease. This market spans senolytic and gene therapy interventions, epigenetic reprogramming technologies, stem cell therapies, NAD+ metabolic modulators, biological age testing platforms utilizing multi-omics analysis, wearable health monitoring devices, AI-driven predictive analytics, and aging-in-place assistive systems.

Market Dynamics:

Driver:

Exponential growth in longevity science investment and breakthrough therapeutic validations

Unprecedented venture capital and corporate investment in longevity science is translating laboratory discoveries into clinical candidates and commercially available health optimization products at an accelerating pace. Landmark research demonstrating epigenetic reprogramming, senolytics, and partial cellular rejuvenation in animal models has galvanized investor interest and established a scientific rationale for developing interventions targeting fundamental aging biology. High-net-worth individuals and sovereign wealth funds are channeling capital into longevity-focused biotechnology companies, longevity clinics, and precision diagnostics platforms, creating a virtuous cycle of investment, innovation, and market expansion that is fundamentally transforming the aging healthcare landscape.

Restraint:

Absence of validated clinical endpoints and regulatory pathways for aging as a therapeutic target

The central scientific and regulatory challenge facing longevity therapeutics is the absence of universally accepted biomarkers for aging as a clinical endpoint, complicating the design of pivotal clinical trials and regulatory submissions. The FDA currently does not recognize aging itself as a disease, limiting the direct regulatory pathway for interventions targeting biological aging mechanisms. Developing validated aging clocks and functional decline biomarkers that regulators accept as surrogate endpoints for longevity therapeutics is a foundational prerequisite for commercialization of this therapeutic category. Extended clinical trial timelines and biomarker validation requirements create lengthy capital consumption periods that challenge the financial models of early-stage longevity companies.

Opportunity:

Direct-to-consumer biological age testing and personalized longevity optimization services

The commercialization of accessible biological age testing through epigenetic clock assays, proteomics panels, and multi-omics platforms is creating a direct-to-consumer market for personalized longevity assessment and optimization programs. Longevity clinics offering comprehensive diagnostic workups combined with individualized supplementation, lifestyle, and therapeutic intervention protocols are attracting affluent early adopters globally. As testing costs decline through sequencing technology democratization, biological age measurement is transitioning from academic research to mainstream consumer health services. Technology companies building AI-powered personalized longevity coaching platforms integrated with wearable biometric monitoring are positioned to capture large-scale consumer market share.

Threat:

Proliferation of unvalidated longevity supplements and ethical concerns around anti-aging claims

The rapid commercialization of longevity technologies has attracted a wave of nutraceutical and supplement products making unsubstantiated anti-aging claims, undermining consumer trust in the broader longevity market and attracting regulatory scrutiny. The blurry boundary between evidence-based longevity interventions and wellness marketing creates reputational risk for credible clinical-stage companies and longevity clinics adhering to rigorous scientific standards. Ethical debates around equitable access to longevity-extending technologies, potential social stratification based on lifespan, and the societal implications of dramatically extended healthspan add complexity to the regulatory and public perception environment for this emerging market.

Covid-19 Impact:

The COVID-19 pandemic amplified public awareness of the vulnerability of aging immune systems, accelerating consumer interest in proactive health optimization and longevity-focused preventive strategies. Pandemic-era health consciousness drove millions of individuals to explore biological age testing, supplement protocols, and lifestyle interventions associated with healthspan improvement. Lockdown periods provided time for personal health reflection and digital health engagement, benefitting longevity platform providers. Post-pandemic health priorities have permanently elevated interest in immune resilience, metabolic health, and aging biology, providing a sustained cultural and commercial tailwind for the longevity and healthy aging technologies market.

The Longevity Therapeutics segment is expected to be the largest during the forecast period

The longevity therapeutics segment commands the largest share within the longevity and healthy aging technologies market, anchored by accelerating investment in senolytics, gene and cell therapies, and NAD+ metabolic modulators advancing through clinical development pipelines. Pharmaceutical companies and specialized longevity biotechs are committing substantial resources to develop interventions targeting hallmarks of aging including cellular senescence, mitochondrial dysfunction, and epigenetic dysregulation.

The Diagnostics and Biomarker Technologies segment is expected to have the highest CAGR during the forecast period

Diagnostics and biomarker technologies are projected to register the highest CAGR within the longevity market, reflecting the growing imperative to objectively measure biological aging trajectories before, during, and after therapeutic and lifestyle interventions. Epigenetic clock tests, proteomics-based biological age panels, and AI-driven multi-omics platforms are transitioning from research tools to commercial diagnostic services. As clinical trials for longevity therapeutics expand, validated biomarker technologies will become critical infrastructure for demonstrating treatment efficacy, driving institutional and biopharma adoption alongside direct-to-consumer uptake through longevity clinics and digital health platforms.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, North America holds the dominant share of the global longevity and healthy aging technologies market, reflecting the region's concentration of longevity-focused biotechnology companies, world-leading research universities, and deep venture capital infrastructure committed to funding aging biology research. The United States hosts the majority of clinical-stage longevity therapeutic developers and commercial longevity clinic networks, alongside a highly engaged affluent consumer base willing to invest in premium health optimization services.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. Asia Pacific is expected to achieve the highest CAGR in the longevity and healthy aging technologies market, driven by Japan's extreme demographic aging, China's strategic national investment in biotechnology and aging research, and rapidly growing wealthy consumer segments in South Korea, Singapore, and Australia seeking premium longevity health services. Regional governments are funding aging research consortia and creating regulatory sandboxes for longevity therapeutics.

Key players in the market

Some of the key players in Global Longevity and Healthy Aging Technologies Market include Altos Labs, Calico Life Sciences, Unity Biotechnology, Retro Biosciences, Insilico Medicine, Juvenescence, BioAge Labs, NewLimit, Life Biosciences, Rejuvenate Bio, Gero, Turn Biotechnologies, AgeX Therapeutics, Genflow Biosciences, and Oisin Biotechnologies.

Key Developments:

In March 2026, Unity Biotechnology announced the initiation of a Phase 2 clinical trial evaluating its next-generation senolytic compound in patients with age-related macular degeneration, with interim efficacy and safety readouts expected within 18 months, representing an important milestone in translating senolytic biology into clinically validated ophthalmology treatments.

In February 2026, Insilico Medicine disclosed positive Phase 1 safety data for its AI-designed longevity therapeutic candidate targeting a novel aging-associated pathway, representing one of the first AI-generated drug molecules to reach clinical evaluation in the longevity field and reinforcing the company's position as a pioneer in AI-driven aging therapeutics development.

Technology Types Covered:

• Longevity Therapeutics
• Diagnostics and Biomarker Technologies
• Digital Health and Monitoring Technologies
• Cognitive and Mental Wellness Technologies
• Aging-in-Place Technologies
• Wellness and Recovery Technologies

Product Types Covered:

• Software Platforms
• Devices and Wearables
• Diagnostic Kits and Testing Services
• Therapeutics and Pharmaceuticals
• Nutraceuticals and Supplements
• Smart Home and Assistive Devices
• Robotics and Automation Systems

Deployment Modes Covered:

• Cloud-Based Solutions
• On-Premise Solutions
• Hybrid Solutions

Distribution Channels Covered:

• Direct Sales
• Online Platforms
• Specialty Clinics
• Retail Pharmacies
• Wellness Centers
• E-commerce Platforms

Applications Covered:

• Healthspan Extension
• Preventive Healthcare
• Chronic Disease Management
• Neurodegenerative Disease Management
• Metabolic Health Management
• Mobility and Rehabilitation
• Cognitive Health Enhancement
• Remote Elderly Care
• Personalized Wellness Management

End Users Covered:

• Hospitals and Clinics
• Longevity Clinics
• Research Institutes and Academic Centers
• Homecare Settings
• Senior Living Communities
• Wellness and Fitness Centers
• Direct-to-Consumer Users
• Insurance and Healthcare Providers

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Longevity and Healthy Aging Technologies Market, By Technology Type

• 5.1 Longevity Therapeutics
  • 5.1.1 Senolytics and Senotherapeutics
  • 5.1.2 Gene and Cell Therapies
  • 5.1.3 Stem Cell Therapies
  • 5.1.4 Epigenetic Reprogramming Technologies
  • 5.1.5 NAD+ and Metabolic Therapies
  • 5.1.6 Regenerative Medicine Technologies
• 5.2 Diagnostics and Biomarker Technologies
  • 5.2.1 Biological Age Testing
  • 5.2.2 Epigenetic Clocks
  • 5.2.3 Multi-Omics Platforms
  • 5.2.4 AI-Based Predictive Analytics
  • 5.2.5 Genomic and Proteomic Testing
• 5.3 Digital Health and Monitoring Technologies
• 5.4 Cognitive and Mental Wellness Technologies
• 5.5 Aging-in-Place Technologies
• 5.6 Wellness and Recovery Technologies

6 Global Longevity and Healthy Aging Technologies Market, By Product Type

• 6.1 Software Platforms
• 6.2 Devices and Wearables
• 6.3 Diagnostic Kits and Testing Services
• 6.4 Therapeutics and Pharmaceuticals
• 6.5 Nutraceuticals and Supplements
• 6.6 Smart Home and Assistive Devices
• 6.7 Robotics and Automation Systems

7 Global Longevity and Healthy Aging Technologies Market, By Deployment Mode

• 7.1 Cloud-Based Solutions
• 7.2 On-Premise Solutions
• 7.3 Hybrid Solutions

8 Global Longevity and Healthy Aging Technologies Market, By Distribution Channel

• 8.1 Direct Sales
• 8.2 Online Platforms
• 8.3 Specialty Clinics
• 8.4 Retail Pharmacies
• 8.5 Wellness Centers
• 8.6 E-commerce Platforms

9 Global Longevity and Healthy Aging Technologies Market, By Application

• 9.1 Healthspan Extension
• 9.2 Preventive Healthcare
• 9.3 Chronic Disease Management
• 9.4 Neurodegenerative Disease Management
• 9.5 Metabolic Health Management
• 9.6 Mobility and Rehabilitation
• 9.7 Cognitive Health Enhancement
• 9.8 Remote Elderly Care
• 9.9 Personalized Wellness Management

10 Global Longevity and Healthy Aging Technologies Market, By End User

• 10.1 Hospitals and Clinics
• 10.2 Longevity Clinics
• 10.3 Research Institutes and Academic Centers
• 10.4 Homecare Settings
• 10.5 Senior Living Communities
• 10.6 Wellness and Fitness Centers
• 10.7 Direct-to-Consumer Users
• 10.8 Insurance and Healthcare Providers

11 Global Longevity and Healthy Aging Technologies Market, By Geography

• 11.1 North America
  • 11.1.1 United States
  • 11.1.2 Canada
  • 11.1.3 Mexico
• 11.2 Europe
  • 11.2.1 United Kingdom
  • 11.2.2 Germany
  • 11.2.3 France
  • 11.2.4 Italy
  • 11.2.5 Spain
  • 11.2.6 Netherlands
  • 11.2.7 Belgium
  • 11.2.8 Sweden
  • 11.2.9 Switzerland
  • 11.2.10 Poland
  • 11.2.11 Rest of Europe
• 11.3 Asia Pacific
  • 11.3.1 China
  • 11.3.2 Japan
  • 11.3.3 India
  • 11.3.4 South Korea
  • 11.3.5 Australia
  • 11.3.6 Indonesia
  • 11.3.7 Thailand
  • 11.3.8 Malaysia
  • 11.3.9 Singapore
  • 11.3.10 Vietnam
  • 11.3.11 Rest of Asia Pacific
• 11.4 South America
  • 11.4.1 Brazil
  • 11.4.2 Argentina
  • 11.4.3 Colombia
  • 11.4.4 Chile
  • 11.4.5 Peru
  • 11.4.6 Rest of South America
• 11.5 Rest of the World (RoW)
  • 11.5.1 Middle East
    • 11.5.1.1 Saudi Arabia
    • 11.5.1.2 United Arab Emirates
    • 11.5.1.3 Qatar
    • 11.5.1.4 Israel
    • 11.5.1.5 Rest of Middle East
  • 11.5.2 Africa
    • 11.5.2.1 South Africa
    • 11.5.2.2 Egypt
    • 11.5.2.3 Morocco
    • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

• 12.1 Industry Value Network and Supply Chain Assessment
• 12.2 White-Space and Opportunity Mapping
• 12.3 Product Evolution and Market Life Cycle Analysis
• 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

• 13.1 Mergers and Acquisitions
• 13.2 Partnerships, Alliances, and Joint Ventures
• 13.3 New Product Launches and Certifications
• 13.4 Capacity Expansion and Investments
• 13.5 Other Strategic Initiatives

14 Company Profiles

• 14.1 Altos Labs
• 14.2 Calico Life Sciences
• 14.3 Unity Biotechnology
• 14.4 Retro Biosciences
• 14.5 Insilico Medicine
• 14.6 Juvenescence
• 14.7 BioAge Labs
• 14.8 NewLimit
• 14.9 Life Biosciences
• 14.10 Rejuvenate Bio
• 14.11 Gero
• 14.12 Turn Biotechnologies
• 14.13 AgeX Therapeutics
• 14.14 Genflow Biosciences
• 14.15 Oisin Biotechnologies

List of Tables

• Table 1 Global Longevity and Healthy Aging Technologies Market Outlook, By Region (2023-2034) ($MN)
• Table 2 Global Longevity and Healthy Aging Technologies Market Outlook, By Technology Type (2023-2034) ($MN)
• Table 3 Global Longevity and Healthy Aging Technologies Market Outlook, By Longevity Therapeutics (2023-2034) ($MN)
• Table 4 Global Longevity and Healthy Aging Technologies Market Outlook, By Senolytics and Senotherapeutics (2023-2034) ($MN)
• Table 5 Global Longevity and Healthy Aging Technologies Market Outlook, By Gene and Cell Therapies (2023-2034) ($MN)
• Table 6 Global Longevity and Healthy Aging Technologies Market Outlook, By Stem Cell Therapies (2023-2034) ($MN)
• Table 7 Global Longevity and Healthy Aging Technologies Market Outlook, By Epigenetic Reprogramming Technologies (2023-2034) ($MN)
• Table 8 Global Longevity and Healthy Aging Technologies Market Outlook, By NAD+ and Metabolic Therapies (2023-2034) ($MN)
• Table 9 Global Longevity and Healthy Aging Technologies Market Outlook, By Regenerative Medicine Technologies (2023-2034) ($MN)
• Table 10 Global Longevity and Healthy Aging Technologies Market Outlook, By Diagnostics and Biomarker Technologies (2023-2034) ($MN)
• Table 11 Global Longevity and Healthy Aging Technologies Market Outlook, By Biological Age Testing (2023-2034) ($MN)
• Table 12 Global Longevity and Healthy Aging Technologies Market Outlook, By Epigenetic Clocks (2023-2034) ($MN)
• Table 13 Global Longevity and Healthy Aging Technologies Market Outlook, By Multi-Omics Platforms (2023-2034) ($MN)
• Table 14 Global Longevity and Healthy Aging Technologies Market Outlook, By AI-Based Predictive Analytics (2023-2034) ($MN)
• Table 15 Global Longevity and Healthy Aging Technologies Market Outlook, By Genomic and Proteomic Testing (2023-2034) ($MN)
• Table 16 Global Longevity and Healthy Aging Technologies Market Outlook, By Digital Health and Monitoring Technologies (2023-2034) ($MN)
• Table 17 Global Longevity and Healthy Aging Technologies Market Outlook, By Cognitive and Mental Wellness Technologies (2023-2034) ($MN)
• Table 18 Global Longevity and Healthy Aging Technologies Market Outlook, By Aging-in-Place Technologies (2023-2034) ($MN)
• Table 19 Global Longevity and Healthy Aging Technologies Market Outlook, By Wellness and Recovery Technologies (2023-2034) ($MN)
• Table 20 Global Longevity and Healthy Aging Technologies Market Outlook, By Product Type (2023-2034) ($MN)
• Table 21 Global Longevity and Healthy Aging Technologies Market Outlook, By Software Platforms (2023-2034) ($MN)
• Table 22 Global Longevity and Healthy Aging Technologies Market Outlook, By Devices and Wearables (2023-2034) ($MN)
• Table 23 Global Longevity and Healthy Aging Technologies Market Outlook, By Diagnostic Kits and Testing Services (2023-2034) ($MN)
• Table 24 Global Longevity and Healthy Aging Technologies Market Outlook, By Therapeutics and Pharmaceuticals (2023-2034) ($MN)
• Table 25 Global Longevity and Healthy Aging Technologies Market Outlook, By Nutraceuticals and Supplements (2023-2034) ($MN)
• Table 26 Global Longevity and Healthy Aging Technologies Market Outlook, By Smart Home and Assistive Devices (2023-2034) ($MN)
• Table 27 Global Longevity and Healthy Aging Technologies Market Outlook, By Robotics and Automation Systems (2023-2034) ($MN)
• Table 28 Global Longevity and Healthy Aging Technologies Market Outlook, By Deployment Mode (2023-2034) ($MN)
• Table 29 Global Longevity and Healthy Aging Technologies Market Outlook, By Cloud-Based Solutions (2023-2034) ($MN)
• Table 30 Global Longevity and Healthy Aging Technologies Market Outlook, By On-Premise Solutions (2023-2034) ($MN)
• Table 31 Global Longevity and Healthy Aging Technologies Market Outlook, By Hybrid Solutions (2023-2034) ($MN)
• Table 32 Global Longevity and Healthy Aging Technologies Market Outlook, By Distribution Channel (2023-2034) ($MN)
• Table 33 Global Longevity and Healthy Aging Technologies Market Outlook, By Direct Sales (2023-2034) ($MN)
• Table 34 Global Longevity and Healthy Aging Technologies Market Outlook, By Online Platforms (2023-2034) ($MN)
• Table 35 Global Longevity and Healthy Aging Technologies Market Outlook, By Specialty Clinics (2023-2034) ($MN)
• Table 36 Global Longevity and Healthy Aging Technologies Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
• Table 37 Global Longevity and Healthy Aging Technologies Market Outlook, By Wellness Centers (2023-2034) ($MN)
• Table 38 Global Longevity and Healthy Aging Technologies Market Outlook, By E-commerce Platforms (2023-2034) ($MN)
• Table 39 Global Longevity and Healthy Aging Technologies Market Outlook, By Application (2023-2034) ($MN)
• Table 40 Global Longevity and Healthy Aging Technologies Market Outlook, By Healthspan Extension (2023-2034) ($MN)
• Table 41 Global Longevity and Healthy Aging Technologies Market Outlook, By Preventive Healthcare (2023-2034) ($MN)
• Table 42 Global Longevity and Healthy Aging Technologies Market Outlook, By Chronic Disease Management (2023-2034) ($MN)
• Table 43 Global Longevity and Healthy Aging Technologies Market Outlook, By Neurodegenerative Disease Management (2023-2034) ($MN)
• Table 44 Global Longevity and Healthy Aging Technologies Market Outlook, By Metabolic Health Management (2023-2034) ($MN)
• Table 45 Global Longevity and Healthy Aging Technologies Market Outlook, By Mobility and Rehabilitation (2023-2034) ($MN)
• Table 46 Global Longevity and Healthy Aging Technologies Market Outlook, By Cognitive Health Enhancement (2023-2034) ($MN)
• Table 47 Global Longevity and Healthy Aging Technologies Market Outlook, By Remote Elderly Care (2023-2034) ($MN)
• Table 48 Global Longevity and Healthy Aging Technologies Market Outlook, By Personalized Wellness Management (2023-2034) ($MN)
• Table 49 Global Longevity and Healthy Aging Technologies Market Outlook, By End User (2023-2034) ($MN)
• Table 50 Global Longevity and Healthy Aging Technologies Market Outlook, By Hospitals and Clinics (2023-2034) ($MN)
• Table 51 Global Longevity and Healthy Aging Technologies Market Outlook, By Longevity Clinics (2023-2034) ($MN)
• Table 52 Global Longevity and Healthy Aging Technologies Market Outlook, By Research Institutes and Academic Centers (2023-2034) ($MN)
• Table 53 Global Longevity and Healthy Aging Technologies Market Outlook, By Homecare Settings (2023-2034) ($MN)
• Table 54 Global Longevity and Healthy Aging Technologies Market Outlook, By Senior Living Communities (2023-2034) ($MN)
• Table 55 Global Longevity and Healthy Aging Technologies Market Outlook, By Wellness and Fitness Centers (2023-2034) ($MN)
• Table 56 Global Longevity and Healthy Aging Technologies Market Outlook, By Direct-to-Consumer Users (2023-2034) ($MN)
• Table 57 Global Longevity and Healthy Aging Technologies Market Outlook, By Insurance and Healthcare Providers (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.